Bipolar Disorder: An Update on Recent Therapeutic Trials

P. Keck, S. McElroy, J. M. Hawkins
{"title":"Bipolar Disorder: An Update on Recent Therapeutic Trials","authors":"P. Keck, S. McElroy, J. M. Hawkins","doi":"10.1097/01.IDT.0000395192.77327.9e","DOIUrl":null,"url":null,"abstract":"LEARNING OBJECTIVES After participating in this activity, the psychiatrist should be better able to:Evaluate the potential benefits of asenapine, paliperidone extended release, quetiapine, and ziprasidone in the treatment of bipolar disorder from new clinical trial results.Analyze the strengths and limitations of data regarding trials of tamoxifen, N-acetyl cysteine, and armodafinil in bipolar disorder.Apply the data from these new studies into evidence-based treatment of patients with bipolar disorder.","PeriodicalId":90307,"journal":{"name":"Psychopharm review : timely reports in psychopharmacology and device-based therapies","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2011-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.IDT.0000395192.77327.9e","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharm review : timely reports in psychopharmacology and device-based therapies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/01.IDT.0000395192.77327.9e","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

LEARNING OBJECTIVES After participating in this activity, the psychiatrist should be better able to:Evaluate the potential benefits of asenapine, paliperidone extended release, quetiapine, and ziprasidone in the treatment of bipolar disorder from new clinical trial results.Analyze the strengths and limitations of data regarding trials of tamoxifen, N-acetyl cysteine, and armodafinil in bipolar disorder.Apply the data from these new studies into evidence-based treatment of patients with bipolar disorder.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
双相情感障碍:最近治疗试验的更新
学习目标:参加本活动后,精神科医生应该能够更好地:从新的临床试验结果中评估阿塞那平、帕利哌酮缓释、喹硫平和齐拉西酮治疗双相情感障碍的潜在益处。分析有关他莫昔芬、n -乙酰半胱氨酸和阿莫达非尼治疗双相情感障碍的试验数据的优势和局限性。将这些新研究的数据应用到双相情感障碍患者的循证治疗中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Treatment of Chronic Pain With Psychotropic Medications Psychopharmacologic Treatments for Alzheimer Disease and Related Dementias Transcranial Direct Current Stimulation for the Treatment of Major Depression Beta-Blockers: Off-Label Use in Psychiatric Disorders Novel Approaches for Managing Schizophrenia: Part I
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1